CRC Research Update — August 24, 2026
Today's colorectal cancer research highlights
mrd
A collection of 32 issues
CRC Research Update — August 22, 2026
Today's colorectal cancer research highlights
New ctDNA assay validated for minimal residual disease monitoring across solid tumors
Skip to content
The CRC Digest
◇ RESEARCH
New ctDNA assay validated for minimal residual disease monitoring across solid tumors
The Haystack MRD assay, a tumor-informed ctDNA test that tracks patient-specific somatic mutations, has been analytically and clinically validated across 23 solid tumor types for detecting minimal residual disease at low
CRC Research Update — August 10, 2026
Today's colorectal cancer research highlights
Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease
Skip to content
The CRC Digest
▪ RESEARCH
Liquid Biopsies Can Monitor CRC Progression and Detect Residual Disease
A translational science review in JAMA reports that circulating tumor DNA (ctDNA) sequencing can identify gene variants to inform treatment selection in colorectal cancer, and that detecting ctDNA after curative intent therapy correlates
Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease
Skip to content
The CRC Digest
Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease
A comprehensive review discusses how ctDNA and immune biomarkers such as mismatch repair deficiency, microsatellite instability, and tumor mutational burden can identify patients at high risk of recurrence and guide adjuvant
Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer
Skip to content
The CRC Digest
◇ RESEARCH
Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer
A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) testing can help predict which stage III colorectal cancer patients are at higher risk of recurrence after surgery. (Clinical Colorectal Cancer)
Dynamic ctDNA Methylation Monitoring Guides Postoperative Surveillance in FIND Trial
Skip to content
The CRC Digest
◆ TRIAL DATA
Dynamic ctDNA Methylation Monitoring Guides Postoperative Surveillance in FIND Trial
A prospective, randomized phase III trial tested whether circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer patients. (Journal of Clinical Oncology)
This content is informational only and
CRC Research Update — July 31, 2026
Today's colorectal cancer research highlights
Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery
Skip to content
The CRC Digest
◆ TRIAL DATA
Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery
The phase II GALAXY study (298 patients) found that ctDNA testing 2-10 weeks after surgery for colorectal liver metastases could help predict which patients are most likely to